Diana Hausman is Chief Medical Officer of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 373,876 shares of ZNTL, which is worth approximately $1.24 Million. The most recent transaction as insider was on May 09, 2024, when has been sold 3,356 shares (Common Stock) at a price of $12.62 per share, resulting in proceeds of $42,352. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 374K
0% 3M change
840.99% 12M change
Total Value Held $1.24 Million

DIANA HAUSMAN Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 09 2024
SELL
Open market or private sale
$42,352 $12.62 p/Share
3,356 Reduced 0.89%
373,876 Common Stock
Feb 01 2024
BUY
Grant, award, or other acquisition
-
337,500 Added 47.22%
377,232 Common Stock
May 08 2023
BUY
Grant, award, or other acquisition
-
39,732 Added 50.0%
39,732 Common Stock

Also insider at

ZYME
Zymeworks Inc. Healthcare
IMRX
Immuneering Corp Healthcare
DH

Diana Hausman

Chief Medical Officer
Vancouver, A1

Track Institutional and Insider Activities on ZNTL

Follow Zentalis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZNTL shares.

Notify only if

Insider Trading

Get notified when an Zentalis Pharmaceuticals, Inc. insider buys or sells ZNTL shares.

Notify only if

News

Receive news related to Zentalis Pharmaceuticals, Inc.

Track Activities on ZNTL